Further Biotechnologies develops regenerative therapies using reprogrammed stem cells derived from supercentenarian donors (110+ years old) who exhibit exceptional resistance to aging and chronic disease. The company aims to translate these individuals' unique genetics into first-in-class treatments that slow aging and extend human healthspan, targeting age-related conditions like heart disease, Alzheimer's, and osteoporosis.
Funding
Funding not disclosed
Founders
Product
Problem
Normal aging is accompanied by decades of chronic diseases—including heart disease, cancer, osteoporosis, frailty, Alzheimer's, and Parkinson's—that afflict roughly 80% of people over 65 and generate trillions of dollars in healthcare costs. Current medicine treats these conditions individually rather than addressing the underlying aging process, leaving most people with a prolonged period of declining health.
Solution
Further Biotechnologies is pioneering regenerative medicine by creating reprogrammed stem cells derived from supercentenarian donors (110+ years old), who maintain disease-free health decades longer than average individuals and are exceptionally rare (~1 in 5 million). By studying and replicating the extraordinary genetics that make these "super agers" age slower with the longest healthspans, the company aims to develop first-in-class therapies that mimic super aging. These therapies are designed to slow down the aging process itself, reducing the burden of multiple age-related diseases simultaneously rather than treating them in isolation. The ultimate goal is to extend human healthspan, allowing people to remain healthier and functional for more years of life.
Target Audience
Primary beneficiaries are adults seeking to extend their healthspan and reduce risk of age-related chronic diseases, with particular relevance for aging populations and patients with early signs of age-associated decline. The company's therapies are also positioned for collaboration with longevity clinics and regenerative medicine providers.
Features
- Reprogrammed stem cell platform derived from supercentenarian donors with verified exceptional longevity and disease resistance
- Access to one of the rarest human populations on Earth (~1 in 5 million) with naturally validated anti-aging genetics
- Therapeutic approach targeting the root causes of aging rather than individual chronic diseases
- Pipeline focused on age-related conditions including heart disease, neurodegeneration, osteoporosis, and frailty
- Research methodology contrasting super-ager biology against normal agers and progeria patients to isolate protective mechanisms